• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有和没有1p杂合性缺失的少突胶质细胞瘤的蛋白质组学比较。

Proteomic comparison of oligodendrogliomas with and without 1pLOH.

作者信息

Okamoto Hiroaki, Li Jie, Gläsker Sven, Vortmeyer Alexander O, Jaffe Howard, Robison R Aaron, Bogler Oliver, Mikkelsen Tom, Lubensky Irina A, Oldfield Edward H, Zhuang Zhengping

机构信息

Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, Maryland 20892-1414, USA.

出版信息

Cancer Biol Ther. 2007 Mar;6(3):391-6. doi: 10.4161/cbt.6.3.3731. Epub 2007 Mar 20.

DOI:10.4161/cbt.6.3.3731
PMID:17264672
Abstract

OBJECTIVE

Chemoresistance is a widespread therapeutic challenge in glial tumors. The molecular basis of chemoresistance is poorly understood, precluding advances in glioma treatment and leaving gliomas among the most lethal tumors. Oligodendrogliomas provide a unique model to study the molecular basis of chemoresistance, as there are two distinct genetic subtypes with significant differences in chemosensitivity. Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH.

METHODS

In order to identify candidate proteins potentially responsible for glioma chemosensitivity, we compared the proteome of four oligodendrogliomas with and five without 1pLOH using comparative proteomic profiling. Proteomic analysis was performed by two-dimensional protein gel electrophoresis and subsequent computerized gel analysis for detection of distinguishing patterns of protein expression. Differentially expressed proteins were identified using Liquid Chromatography/Mass Spectrometry. Differential expression of select proteins was confirmed by Western blotting.

RESULTS

We identified seven candidate proteins that are overexpressed in oligodendrogliomas without 1pLOH. Two of these proteins (glyoxalase I and Rho GDP dissociation inhibitor) have previously been shown to enhance chemoresistance in other tumors. In turn, we identified twelve overexpressed proteins in tumors with 1pLOH that have previously been reported to induce chemosensitivity in other forms of human neoplasia.

CONCLUSIONS

These identified proteins are potential targets for pharmacological therapy and may also be useful as biomarkers for differentiation of chemoresistant and chemosensitive oligodendroglioma.

摘要

目的

化疗耐药是胶质肿瘤中普遍存在的治疗挑战。化疗耐药的分子基础尚不清楚,这阻碍了胶质瘤治疗的进展,使胶质瘤成为最致命的肿瘤之一。少突胶质细胞瘤提供了一个研究化疗耐药分子基础的独特模型,因为存在两种不同的基因亚型,其化疗敏感性有显著差异。尽管形态学相似度高,但染色体1短臂等位基因缺失(1pLOH)的肿瘤比无1pLOH的肿瘤对化疗更敏感。

方法

为了鉴定可能与胶质瘤化疗敏感性相关的候选蛋白,我们使用比较蛋白质组学分析方法,比较了4例有1pLOH和5例无1pLOH的少突胶质细胞瘤的蛋白质组。蛋白质组分析通过二维蛋白质凝胶电泳及随后的计算机凝胶分析来检测蛋白质表达的差异模式。使用液相色谱/质谱法鉴定差异表达的蛋白质。通过蛋白质印迹法确认所选蛋白质的差异表达。

结果

我们鉴定出7种在无1pLOH的少突胶质细胞瘤中过表达的候选蛋白。其中两种蛋白(乙二醛酶I和Rho GDP解离抑制剂)先前已被证明可增强其他肿瘤的化疗耐药性。反过来,我们在有1pLOH的肿瘤中鉴定出12种过表达的蛋白,这些蛋白先前已被报道可诱导其他形式人类肿瘤的化疗敏感性。

结论

这些鉴定出的蛋白是药物治疗的潜在靶点,也可能作为区分化疗耐药和化疗敏感少突胶质细胞瘤的生物标志物。

相似文献

1
Proteomic comparison of oligodendrogliomas with and without 1pLOH.有和没有1p杂合性缺失的少突胶质细胞瘤的蛋白质组学比较。
Cancer Biol Ther. 2007 Mar;6(3):391-6. doi: 10.4161/cbt.6.3.3731. Epub 2007 Mar 20.
2
Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p.有和没有1p等位基因缺失的少突胶质细胞瘤基因表达谱的差异
Oncogene. 2002 Jun 6;21(25):3961-8. doi: 10.1038/sj.onc.1205495.
3
ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties.ATAD 3A和ATAD 3B是位于1号染色体短臂远端的基因,在人类胶质瘤细胞系中差异表达,并具有体外抗肿瘤和抗化疗特性。
Exp Cell Res. 2008 Sep 10;314(15):2870-83. doi: 10.1016/j.yexcr.2008.06.017. Epub 2008 Jul 1.
4
iTRAQ-based quantitative proteomic analysis for identification of oligodendroglioma biomarkers related with loss of heterozygosity on chromosomal arm 1p.基于 iTRAQ 的定量蛋白质组学分析鉴定与染色体 1p 臂杂合性缺失相关的少突胶质细胞瘤标志物。
J Proteomics. 2012 Dec 21;77:480-91. doi: 10.1016/j.jprot.2012.09.028. Epub 2012 Oct 4.
5
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.91例星形细胞瘤和少突胶质细胞瘤中1p、19q、10q、TP53、EGFR、CDK4和CDKN2A的组织学与分子遗传学分析的相关性
Clin Cancer Res. 2002 Jan;8(1):196-201.
6
Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.胶质瘤中1p36和19q13的等位基因缺失:与组织学分类的相关性、1p36上150kb最小缺失区域的定义以及CAMTA1作为候选肿瘤抑制基因的评估
Clin Cancer Res. 2005 Feb 1;11(3):1119-28.
7
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.寡突胶质细胞瘤中表达突变型异柠檬酸脱氢酶-1 的蛋白质组学分析。
Proteomics. 2011 Nov;11(21):4139-54. doi: 10.1002/pmic.201000646. Epub 2011 Sep 22.
8
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.间变性少突胶质细胞瘤患者化疗反应和生存的特定基因预测指标
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9. doi: 10.1093/jnci/90.19.1473.
9
The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas.1p编码蛋白Stathmin与恶性胶质瘤对亚硝基脲的耐药性
J Natl Cancer Inst. 2007 Apr 18;99(8):639-52. doi: 10.1093/jnci/djk135.
10
[Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].[1号和19号染色体杂合性缺失与胶质瘤中MGMT、p53和Ki-67蛋白表达的相关性]
Zhonghua Zhong Liu Za Zhi. 2011 Oct;33(10):752-8.

引用本文的文献

1
A unique four-hub protein cluster associates to glioblastoma progression.一种独特的四枢纽蛋白簇与胶质母细胞瘤进展相关。
PLoS One. 2014 Jul 22;9(7):e103030. doi: 10.1371/journal.pone.0103030. eCollection 2014.
2
Proteomic analysis of glioma chemoresistance.脑胶质瘤化疗耐药的蛋白质组学分析。
Curr Neuropharmacol. 2012 Mar;10(1):72-9. doi: 10.2174/157015912799362733.
3
Proteomics of gliomas: initial biomarker discovery and evolution of technology.脑胶质瘤的蛋白质组学:初步生物标志物的发现和技术的发展。
Neuro Oncol. 2011 Sep;13(9):926-42. doi: 10.1093/neuonc/nor078.
4
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.曲格列酮降低脑胶质瘤中糖氧还蛋白 I 蛋白的表达,并增强化疗药物的作用。
J Oncol. 2010;2010:373491. doi: 10.1155/2010/373491. Epub 2010 May 4.
5
Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion.伴有和不伴有 1p/19q 缺失的少突胶质细胞瘤的定量蛋白质组学分析。
J Proteome Res. 2010 May 7;9(5):2610-8. doi: 10.1021/pr100054v.
6
Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.对染色体臂 1p 和 19q 杂合性缺失的人神经胶质瘤进行差异蛋白质组分析。
Neuro Oncol. 2010 Mar;12(3):243-56. doi: 10.1093/neuonc/nop025. Epub 2010 Jan 7.
7
Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.纤维型和脑膜皮型骨侵袭性与非侵袭性良性脑膜瘤的蛋白质组学特征存在差异。
J Neurooncol. 2009 Sep;94(3):321-31. doi: 10.1007/s11060-009-9865-9. Epub 2009 Apr 7.